Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer
In conclusion, this study demonstrates that WG-391D exhibits strong antitumor activity against ovarian cancer and indicates that the down-regulation of CDC25B by inhibitors could provide a rationale for ovarian cancer therapy. Introduction Ovarian cancer is one of the most common malignances in females. The American Cancer Society estimated that there were 22,240 cases of ovarian cancer, and 14,070 deaths, in the United States in 2018 (1). During its early stages, ovarian cancer can be asymptomatic; hence, ~70% of patients have advanced disease when diagnosed and ultimately develop chemotherapeutic drug resistance and tumor recurrence (2). The death rate from ovarian cancer worldwide has remained as high as 60% over the previous two decades, giving this cancer the highest mortality rate of all gynecological malignances (1, 3). Novel reagents or treatment strategies, particularly for tumors resistant to chemotherapy, are therefore needed to improve the outcomes of surgery and chemotherapy in ovarian cancer patients (2). As an increasing number of mechanisms underlying ovarian carcinogenesis and progression are being uncovered, opportunities arise for the development of novel therapeutic drugs with which to improve patient survival by targeting specific cancer-associated molecules. In preclinical and clinical studies, a growing number of drugs and strategies have been adopted to prevent disease progression, inhibit recurrence, and reverse drug resistance to chemotherapeu...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Cheng Han, Yinping Zhang, Marc Redmile-Gordon, Huan Deng, Zhenggui Gu, Qiguo Zhao, Fang Wang
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Peter A. Bain, Adrienne Gregg, Alok K. Pandey, Mohana Krishna Reddy Mudiam, Peta A. Neale, Anu Kumar
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Jinquan Chen, Xuan Li, Wei Jia, Shili Shen, Shengjiong Deng, Bohua Ji, Junjun Chang
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Publication date: Available online 30 September 2020Source: Journal of Hazardous MaterialsAuthor(s): Anthony Beauvois, Delphine Vantelon, Jacques Jestin, Martine Bouhnik-Le Coz, Charlotte Catrouillet, Valérie Briois, Thomas Bizien, Mélanie Davranche
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
CONCLUSION: In this study, no influence of tear substitutes containing different viscosities of hyaluronic acid on the measurement results of optical coherence tomography could be determined. Therefore, 0.1%, 0.2% and 0.3% hyaluronic acid can be applied to the patient to improve the corneal surface before the examination with optical coherence tomography, without influencing the measurement results of optical coherence tomography. PMID: 33036058 [PubMed - as supplied by publisher]
More News: Academia | Adenocarcinoma | Alcoholism | Biology | Biotechnology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Chemistry | Chemotherapy | Child Development | Children | China Health | Chloride | Clear Cell Carcinoma | Clinical Trials | Colon Cancer | Colorectal Cancer | Databases & Libraries | Education | Endometrial Cancer | Endometrioid Carcinoma | Epithelial Cancer | Esophagus Cancer | Gastroschisis Repair | Genetics | Germany Health | Grants | Hematology | Hepatocellular Carcinoma | Immunotherapy | Italy Health | Japan Health | Laboratory Medicine | Liver | Liver Cancer | Medical Ethics | Molecular Biology | Mucinous Carcinoma | Mucinous Ovarian Cancer | Non-Small Cell Lung Cancer | OBGYN | Organic | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Penicillin | Reproduction Medicine | Science | Serous Carcinoma | Skin Cancer | Squamous Cell Carcinoma | Statistics | Students | Study | Taiwan Health | Universities & Medical Training | Urology & Nephrology | USA Health | Vitamin K | Vitamins | Websites | Weight Loss